• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

3 Marijuana Stocks Moving in the Pre-Market Session

August 15, 2018

 

As many know, the regular North American trading day takes place between the opening bell at 9:30 AM EST and the closing bell at 4:00 PM EST. For the early-rising serious traders who are looking to get an edge, there is the pre-market session. Movement in the pre-market session can be an indicator of how the rest of the day will play out. Here’s the marijuana stocks that are moving in the pre-market session today.

 

Canopy Growth Corp. (NYSE:CGC) is trading up at $35.75 USD per share in the NYSE pre-market session. Shares of CGC closed the trading session on Tuesday, August 14th at $24.62 USD per share. This represents a rise of roughly 45.21%. Late last night, Canopy released financial and operating results for the first quarter of fiscal 2019. Early this morning, the company also announced that Constellation Brands will increase its ownership interest in Canopy Growth by acquiring 104.5 million shares directly from Canopy Growth, thereby achieving approximately 38 percent ownership when assuming exercise of the existing Constellation warrants.

 

Cronos Group Inc. (NASDAQ:CRON) is trading up at $6.37 USD per share in the NASDAQ pre-market session. Shares of CRON closed the trading session on Tuesday, August 14th at $5.65 USD per share. This represents a rise of roughly 12.74%. Yesterday, Cronos Group released financial results for the second quarter that ended June 30, 2018, showing 428% year-over-year sales growth.


GW Pharmaceuticals Plc. (NASDAQ:GWPH) is trading up at $139.66 USD per share in the NASDAQ pre-market session. Shares of GWPH closed the trading session on Tuesday, August 14th at $133.48 USD per share. This represents a rise of roughly 4.63%. Recently, it was announced that the company would be selling its recently approved CBD drug for over $32,000 per year.

 

Conclusion


To stay up-to-the-minute, be sure to subscribe to Marijuana Stock Updates here.

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.